Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical products company Taro Pharmaceutical Industries (NYSE:TARO) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Taro and see what CAPS investors are saying about the stock right now.

Taro facts

Headquarters (founded)

Haifa Bay, Israel (1959)

Market Cap

$2.4 billion



Trailing-12-Month Revenue

$688.4 million


Interim CEO James Kedrowski
Interim CFO Michael Kalb

Trailing-12-Month Operating Margin



$479.1 million / $28.3 million


Sandoz International
Teva Pharmaceutical Industries

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 92% of the 50 members who have rated Taro believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star DrGoldin, succinctly summed up the Taro bull case for our community: "What's not to like? Margins and returns at the high end of the industry, with nothing but consistent growth for the future. All this at a modest p/e (however you wish to calculate it). And clean sheets!"

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.